October 8, 2015 Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; Contract Negotiations Underway With Initial Clinical Site. BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase …
Mon Sep 14, 2015 9:30am EDT BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM) Also Provides General Corporate Update Including Consolidation of Its Corporate Headquarters and Research Laboratories in San Francisco Bay Area; Attends NYC Biotechnology Conference and Posts Updated Investor Presentation VANCOUVER, BC–(Marketwired – September 14, 2015) – BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX …
2015 Jul 15 Hired Dr. M. Lacher –Head of R&D -an expert in immuno-oncology & diagnostics
2015 June 24 BriaCell begins trading on the OTCQB (BCTXF)
2015 Jun 16 Signed Definitive Agreement of Manufacturing of BriaVax at cGMP Facility- UC, Davis Health Center
2015 Jun 1 Hired seasoned biotech veteran Dr. Joseph Wagner as President and Chief Executive Officer
2014 Nov 27 BriaCell Therapeutics Corp. completes its Initial Public Offering (IPO), & raises $US2.0M, trades at TSX Venture (BCT.V)
2014 April 3 Incorporated as a private Delaware company